Intralesional curettage for grades II and III giant cell tumors of bone

Richard D. Lackman, Harish S. Hosalkar, Christian M. Ogilvie, Jesse T. Torbert, Edward Fox

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Grade III Campanacci lesions are traditionally treated with wide resections based on their postulated aggressiveness and potential for local recurrence and metastasis. The purpose of this study was to determine if there was a difference in local recurrence rates of Grade II and III lesions treated with intralesional curettage, burring, phenol cauterization, and polymethylmethacrylate application. Sixty-three patients (26 Campanacci Grade II and 37 Grade III lesions) met the inclusion criteria. No pathologic fractures, including intraarticular fractures, were included in this study. Followup averaged 108 months (range, 25-259 months). The overall local recurrence rate was 6% (4 of 63 patients), with no observed difference between Grade II and III lesions. The average Musculoskeletal Tumor Society functional score was 27.9/30 (93%). The mean range of motion of the adjacent joint was 97%. Patients with radiographic signs of osteoarthritis before treatment did not show substantial progression, and only one patient developed radiographic signs of degenerative arthritis postoperatively. Our distal metastatic rate was 3.2%. These data support the use of intralesional curettage and burring with adjuvant phenol and polymethylmethacrylate even in Grade III lesions, in the absence of pathologic fracture, regardless of the presence or extent of extraosseous extension. Level of Evidence: Therapeutic study, Level III-1 (retrospective cohort).

Original languageEnglish (US)
Pages (from-to)123-127
Number of pages5
JournalClinical Orthopaedics and Related Research
Issue number438
DOIs
StatePublished - Jan 1 2005

Fingerprint

Giant Cell Tumor of Bone
Curettage
Spontaneous Fractures
Polymethyl Methacrylate
Phenol
Recurrence
Osteoarthritis
Intra-Articular Fractures
Cautery
Articular Range of Motion
Neoplasm Metastasis
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Lackman, Richard D. ; Hosalkar, Harish S. ; Ogilvie, Christian M. ; Torbert, Jesse T. ; Fox, Edward. / Intralesional curettage for grades II and III giant cell tumors of bone. In: Clinical Orthopaedics and Related Research. 2005 ; No. 438. pp. 123-127.
@article{2626043fb909451f98b156b75f88964b,
title = "Intralesional curettage for grades II and III giant cell tumors of bone",
abstract = "Grade III Campanacci lesions are traditionally treated with wide resections based on their postulated aggressiveness and potential for local recurrence and metastasis. The purpose of this study was to determine if there was a difference in local recurrence rates of Grade II and III lesions treated with intralesional curettage, burring, phenol cauterization, and polymethylmethacrylate application. Sixty-three patients (26 Campanacci Grade II and 37 Grade III lesions) met the inclusion criteria. No pathologic fractures, including intraarticular fractures, were included in this study. Followup averaged 108 months (range, 25-259 months). The overall local recurrence rate was 6{\%} (4 of 63 patients), with no observed difference between Grade II and III lesions. The average Musculoskeletal Tumor Society functional score was 27.9/30 (93{\%}). The mean range of motion of the adjacent joint was 97{\%}. Patients with radiographic signs of osteoarthritis before treatment did not show substantial progression, and only one patient developed radiographic signs of degenerative arthritis postoperatively. Our distal metastatic rate was 3.2{\%}. These data support the use of intralesional curettage and burring with adjuvant phenol and polymethylmethacrylate even in Grade III lesions, in the absence of pathologic fracture, regardless of the presence or extent of extraosseous extension. Level of Evidence: Therapeutic study, Level III-1 (retrospective cohort).",
author = "Lackman, {Richard D.} and Hosalkar, {Harish S.} and Ogilvie, {Christian M.} and Torbert, {Jesse T.} and Edward Fox",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.blo.0000180051.27961.c3",
language = "English (US)",
pages = "123--127",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "438",

}

Intralesional curettage for grades II and III giant cell tumors of bone. / Lackman, Richard D.; Hosalkar, Harish S.; Ogilvie, Christian M.; Torbert, Jesse T.; Fox, Edward.

In: Clinical Orthopaedics and Related Research, No. 438, 01.01.2005, p. 123-127.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intralesional curettage for grades II and III giant cell tumors of bone

AU - Lackman, Richard D.

AU - Hosalkar, Harish S.

AU - Ogilvie, Christian M.

AU - Torbert, Jesse T.

AU - Fox, Edward

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Grade III Campanacci lesions are traditionally treated with wide resections based on their postulated aggressiveness and potential for local recurrence and metastasis. The purpose of this study was to determine if there was a difference in local recurrence rates of Grade II and III lesions treated with intralesional curettage, burring, phenol cauterization, and polymethylmethacrylate application. Sixty-three patients (26 Campanacci Grade II and 37 Grade III lesions) met the inclusion criteria. No pathologic fractures, including intraarticular fractures, were included in this study. Followup averaged 108 months (range, 25-259 months). The overall local recurrence rate was 6% (4 of 63 patients), with no observed difference between Grade II and III lesions. The average Musculoskeletal Tumor Society functional score was 27.9/30 (93%). The mean range of motion of the adjacent joint was 97%. Patients with radiographic signs of osteoarthritis before treatment did not show substantial progression, and only one patient developed radiographic signs of degenerative arthritis postoperatively. Our distal metastatic rate was 3.2%. These data support the use of intralesional curettage and burring with adjuvant phenol and polymethylmethacrylate even in Grade III lesions, in the absence of pathologic fracture, regardless of the presence or extent of extraosseous extension. Level of Evidence: Therapeutic study, Level III-1 (retrospective cohort).

AB - Grade III Campanacci lesions are traditionally treated with wide resections based on their postulated aggressiveness and potential for local recurrence and metastasis. The purpose of this study was to determine if there was a difference in local recurrence rates of Grade II and III lesions treated with intralesional curettage, burring, phenol cauterization, and polymethylmethacrylate application. Sixty-three patients (26 Campanacci Grade II and 37 Grade III lesions) met the inclusion criteria. No pathologic fractures, including intraarticular fractures, were included in this study. Followup averaged 108 months (range, 25-259 months). The overall local recurrence rate was 6% (4 of 63 patients), with no observed difference between Grade II and III lesions. The average Musculoskeletal Tumor Society functional score was 27.9/30 (93%). The mean range of motion of the adjacent joint was 97%. Patients with radiographic signs of osteoarthritis before treatment did not show substantial progression, and only one patient developed radiographic signs of degenerative arthritis postoperatively. Our distal metastatic rate was 3.2%. These data support the use of intralesional curettage and burring with adjuvant phenol and polymethylmethacrylate even in Grade III lesions, in the absence of pathologic fracture, regardless of the presence or extent of extraosseous extension. Level of Evidence: Therapeutic study, Level III-1 (retrospective cohort).

UR - http://www.scopus.com/inward/record.url?scp=24344465719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344465719&partnerID=8YFLogxK

U2 - 10.1097/01.blo.0000180051.27961.c3

DO - 10.1097/01.blo.0000180051.27961.c3

M3 - Article

C2 - 16131880

AN - SCOPUS:24344465719

SP - 123

EP - 127

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 438

ER -